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Abstract
MiRNAs regulate gene expression at a post-transcriptional level and their dysregulation can play major roles in the
pathogenesis of many different forms of cancer, including neuroblastoma, an often fatal paediatric cancer originating from
precursor cells of the sympathetic nervous system. We have analyzed a set of neuroblastoma (n=145) that is broadly
representative of the genetic subtypes of this disease for miRNA expression (430 loci by stem-loop RT qPCR) and for DNA
copy number alterations (array CGH) to assess miRNA involvement in disease pathogenesis. The tumors were stratified and
then randomly split into a training set (n=96) and a validation set (n=49) for data analysis. Thirty-seven miRNAs were
significantly over- or under-expressed in MYCN amplified tumors relative to MYCN single copy tumors, indicating a potential
role for the MYCN transcription factor in either the direct or indirect dysregulation of these loci. In addition, we also
determined that there was a highly significant correlation between miRNA expression levels and DNA copy number,
indicating a role for large-scale genomic imbalances in the dysregulation of miRNA expression. In order to directly assess
whether miRNA expression was predictive of clinical outcome, we used the Random Forest classifier to identify miRNAs that
were most significantly associated with poor overall patient survival and developed a 15 miRNA signature that was
predictive of overall survival with 72.7% sensitivity and 86.5% specificity in the validation set of tumors. We conclude that
there is widespread dysregulation of miRNA expression in neuroblastoma tumors caused by both over-expression of the
MYCN transcription factor and by large-scale chromosomal imbalances. MiRNA expression patterns are also predicative of
clinical outcome, highlighting the potential for miRNA mediated diagnostics and therapeutics.
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Introduction
Neuroblastoma,one ofthe mostcommonsolid tumours inchildren,
accounts for 15% of childhood cancer deaths [1]. Heterogeneity in the
clinical behaviour of these tumors is remarkable, ranging from
spontaneous regression to aggressive clinical course and death due to
disease. Many biological factors such as patient age, ploidy, disease
stage and histopathological characteristics are partially predictive of
clinical outcome. Tumours in infants that are characterized by
hyperdiploidy have a high propensity to spontaneously regress or
differentiate into benign ganglioneuroma, even when the disease is
widely disseminated. In contrast, tumours from children over 18
months of age are usually metastatic at diagnosis, often become
refractory to treatment, and exhibit many recurrent chromosomal
imbalances and/or amplification of the MYCN oncogene.
Amplification of the MYCN transcription factor was one of the first
genetic abnormalities to be associated with poor clinical outcome in
neuroblastoma [2]. A number of large scale chromosomal imbalances,
including lossof either 1p or 11q or gain of17q,are also associated with
poor survival [3–5]. MYCN amplification (MNA) and loss of 11q are
inversely related, defining independent genetic subtypes of the disease,
with loss of chromosome 1p occurring preferentially in MNA tumors,
and loss of 3p with 11q- tumors [6,7].
The deregulation of microRNAs (miRNA) has recently been
implicated in the pathogenesis of neuroblastoma. MiRNAs
regulate gene expression at a post-transcriptional level by
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degraded. They play major roles in the differentiation of neural
cells [8], and the deregulation of these sequences can contribute to
tumorigenesis in many forms of cancer (see [9] for review). In
neuroblastoma, studies have demonstrated that miR-34a, mapping
to a region on chromosome 1p that is often deleted in high stage
disease, acts as a tumor suppressor [10–12], as ectopic over-
expression of this miRNA decreases cell proliferation through the
induction of apoptosis. In addition, some miRNAs, such as miR-
17-5p, behave in an oncogenic manner in these tumors, being
directly up-regulated by MYCN [13].
Expression profiling of miRNAs in neuroblastomas has identified
a number of miRNAs that are differentially expressed in favourable
versus unfavourable tumor subtypes, particularly with respect to
MNA versus non-MNA tumors [13–15]. However, these studies
have been limited with respect to the number of tumors examined,
with the largest study involving only 35 tumors profiled for 150
miRNAs [14]. Direct association of miRNA expression with patient
survival could not be accomplished in such small data sets. Here, we
expression profile 430 miRNA loci in 145 tumors that have also
been characterized by high resolution aCGH, allowing identifica-
tion of miRNAs which are associated with patient survival,
differentially expressed in genetic subtypes, and that have been
dysregulated by both over-expression of the MYCN transcription
factor and large-scale chromosomal imbalances.
Results
Analysis of Somatically Acquired DNA Copy Number
Alterations
High resolution aCGHanalysis was carried out on all 145 primary
neuroblastoma tumours in order to identify DNA copy number
alterations and to classify the tumors into major genetic subtypes
(MYCN amplified, chromosome 11q loss etc). Thirty-six tumors had
MYCN amplification (MNA), four of which also had large-scale
hemizygous loss of chromosome 11q material. In total, 42 tumors
exhibited loss of chromosome 11q material without MNA. Many
additional recurrent genomic imbalances, such as loss of 1p, 3p and
gainof17q,were also detected. For tumorsthatdid not have MNA or
11q loss, 22 were derived from patients with stage 4 disease, while 45
came from patients with stage 1, 2, 3 or 4s disease.
A miRNA Expression Profile Associated with MYCN
Amplified Tumors
Of the 430 miRNAs profiled in this study, 132 were expressed
in fewer than 10 tumors, so that the final dataset comprised 298
miRNAs expressed in at least 10 samples (Table S1).
Given the importance of MYCN amplification in neuroblasto-
ma, we initially identified miRNAs that were differentially
expressed between MNA versus non-MNA tumors using the
Wilcoxon Rank test based p-values corrected for multiple
comparisons (using the training set of tumors, n=96). A total of
37 miRNAs were significantly differentially expressed (p,0.05)
with respect to MNA and are likely directly or indirectly regulated
by MYCN. Fourteen miRNAs were over-expressed while 23 were
under-expressed, as illustrated in Figure 1. Excluding members of
the same polycistronic cluster, or major versus minor forms of the
same miRNA locus, there were 8 over-expressed and 19 under-
expressed independent miRNA transcriptional units.
As one would expect, two-way hierarchical cluster analysis with
this set of miRNAs showed significant clustering of MNA tumors
in both the training set (Figure 1) and the validation set of tumors
(Figure 2). Six MNA tumors were misclassified, and a number of
non-MNA tumors clustered within the major MNA clusters. The
patients from the cluster (A) enriched for MNA tumors had
significantly poorer event free survival (EFS) and overall survival
(OS) than did the non-MNA cluster (B) in both the training and
validation tumor sets (P values ranging from 0.0013 to 0.031).
Analysis of survival of patients falling into smaller subclusters did
not yield significant P values.
Two major miRNA expression clusters were discernable
following cluster analysis with the MNA associated miRNA
signature (Figure 1). One cluster was over-expressed in MNA
tumors, while the other was under-expressed. Among the miRNAs
over-expressed in MNA tumors was the polycistronic cluster miR-
17-5p-92. This cluster has been previously reported to be highly
expressed in MNA tumors [13–15].
In order to test the possibility that MYCN is either directly or
indirectlyregulatingtheexpressionofmiRNAlociinanexperimental
system, TLDA microfluidic cards (368 miRNAs) were used to profile
the MYCN inducible cell line, SHEP-TET21. SHEP-TET21 is a ‘tet-
off’ cell line, only expressing MYCN in the absence of doxycycline
(Figure S1). Using a fold change cut-off of #21.5 or $+1.5, twenty-
nine miRNAs were differentially expressed in MYCN ‘on’ compared
to MYCN ‘off’ cells (Table S2). Nine out of these 29 miRNAs (31.0%)
also showed differential expression in MNA versus non-MNA tumors.
The direction of miRNA expressional change was identical in SHEP
cellsandtumors.Itshouldbeemphasizedthattheseexperimentsonly
provide a correlation between MYCN expression change and
miRNA expressional alterations, and that further experiments
involving chromatin immunoprecipitation are required to distinguish
between the direct and indirect effects of this transcription factor.
Many reasons exist as to why the cell line repressible system had only
31% overlap with the tumors. For example, there could be very
substantial differences in the promoter regions of the miRNA loci in
t h eS H E Pc e l ll i n ev e r s u st h et u m o r s ,a sw e l la sd i f f e r e n c e si nt h e
expression of other transcription factors/repressors.
Identification of a miRNA Expression Signature Predictive
of Clinical Outcome
Although the 37 miRNAs associated with MYCN expression
levels was somewhat predictive of clinical outcome, we reasoned
that a better signature could be derived by identifying miRNAs
that are specifically associated with survival, given that many of the
miRNAs in the MYCN signature might be only passively involved
with tumorigenesis, and because other genetic subtypes, such as
those with 11q loss, are also associated with poor survival. We used
the Random Forest classifier to identify the top 15 miRNAs whose
expression was most significantly associated with patient overall
survival from the training set of tumors. Hierarchical cluster
analysis with the top 15 miRNAs from this list produced two major
clusters (A and B) which differed significantly in survival in both
the training (p,0.0001) (Figure 3) and validation tumor sets
(p,0.002)(Figure 4). Cluster B could be further split into two
subclusters (B1 and B2) with minor, although statistically
significant differences in survival characteristics (Figure 3 and 4).
For overall survival in the validation tumor set, this miRNA
expression signature had a sensitivity of 72.7%, a specificity of
86.5%, a positive predictive value of 61.5% and a negative
predictive value of 91.4%. Two miRNAs, miR-190 and miR-572,
in the miRNA survival signature were also significantly differen-
tially expressed in MNA tumors versus non-MNA tumors.
MiRNA Expression Is Dysregulated by DNA Copy Number
Alterations
In order to determine if large-scale genomic gains and losses
might have widely impacted upon miRNA expression, we
miRNA and Neuroblastoma
PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7850Figure 1. Two-way hierarchical cluster analysis on the training set of tumors (n=96) using 37 miRNAs that were significantly
differentially expressed between MNA and non-MNA tumors. Tumor cluster A was significantly enriched for MNA tumors (69%). The Kaplan-
Meier graphs at the bottom of the figure show that EFS and OS was significantly reduced in the MNA tumor cluster (Cluster A) relative to the non-
MNA cluster (Cluster B).
doi:10.1371/journal.pone.0007850.g001
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7850Figure 2. Two-way hierarchical cluster analysis on the validation set of tumors (n=48) using 37 miRNAs that were significantly
differentially expressed between MNA and non-MNA tumors. Tumor cluster A was significantly enriched for stage 4 tumors with MNA
tumors. The Kaplan-Meier graphs at the bottom of the figure show that EFS and OS was significantly reduced in the MNA tumor cluster (Cluster A)
relative to the non-MNA cluster (Cluster B).
doi:10.1371/journal.pone.0007850.g002
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aCGH on each tumor, with relative miRNA expression values.
Only miRNAs expressed in a minimum of 10 tumors and mapping
to regions exhibiting loss or gain in a minimum of 5 tumors were
included in our analysis. A total of 51 miRNA loci exhibited
significant (P,0.05) differences in mean expression between
tumors exhibiting a copy number alteration versus those with
diploid status (Table S3 and Figure 5A–I). Because some loci
(Figure 5A to C) were deleted in some tumors, and gained in
others, there were a total of 62 genomic events affecting these 51
miRNA. In 47 instances, the alterations in miRNA expression
were concordant with the DNA copy number change, e.g. lower
expression for deletions, higher expression for DNA copy number
gains. Although there were 15 instances where miRNA expres-
Figure 3. Two-way hierarchical cluster analysis on the training set of tumors (n=96) using the top 15 miRNAs that were
significantly associated with OS, as determined by the Random Forest classifier. As illustrated by the Kaplan-Meier graphs at the bottom
of the figure, the patients from the two major cluster (A and B) differed dramatically in both EFS and OS. Cluster A is highly enriched for stage 4
tumors with MNA or loss of 11q and for patients with EFS and OS events. Notably, subclusters (B1 and B2) within the major cluster B showed a minor,
but statistically significant difference in both EFS and OS.
doi:10.1371/journal.pone.0007850.g003
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PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7850Figure 4. Two-way hierarchical cluster analysis on the validation set of tumors (n=48) using the top 15 miRNAs that were
significantly associated with OS, as determined by the Random Forest classifier. Similar to the training set of tumors, cluster A is highly
enriched for stage 4 tumors with MNA or loss of 11q and for patients with EFS and OS events. As illustrated by the Kaplan-Meier graphs at the bottom
of the figure, the patients from the two major clusters (A and B) differed dramatically in both EFS and OS. Notably, subclusters (B1 and B2) within the
major cluster B showed a minor, but statistically significant difference in both EFS and OS.
doi:10.1371/journal.pone.0007850.g004
miRNA and Neuroblastoma
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the skewing towards concordant events (47 to 15) was highly non-
random (p=0.0002), leading us to conclude that genomic
imbalances have significantly altered the expression levels of
approximately 15% of all miRNA loci used in our expression
profiling study.
Discussion
Our results indicate that amplification of the MYCN transcrip-
tion factor has significantly affected miRNA expression in
neuroblastoma tumors, consistent with our earlier observations
[14] and the observations of other groups [13,15]. Our present
studies, based on a larger set of miRNAs and tumors than what
was previously studied, has permitted us to identify many
additional miRNAs whose expression levels are correlated with
MYCN levels. In addition, we demonstrate that many of the
recurrent large-scale chromosomal imbalances, including loss of
1p, 3p, 11q and 14q, along with gain of 1q and 17q, have also had
a major impact upon miRNA expression. Our finding that
approximately 15% of miRNA loci have expressional changes
attributable to genomic imbalances is comparable to the results of
Zhang et al [16] showing that 15% of miRNAs are deregulated by
such alterations in ovarian cancer. Interestingly, we identified
Figure 5. Representative box-plots illustrating correlation between miRNA expression and DNA copy number status. MiRNA locus,
map location and p-value are displayed at the top of each box-plot while number of tumors having deletion, gain or normal DNA copy number status
are displayed at the bottom. A through C are examples of miRNA expressional changes for regions that were both lost and gained in tumors. D
through G are miRNA expressional changes for regions that showed only loss in the tumors, while H is an example of a miRNA mapping to a region
that only showed gain in the entire tumor cohort. In the examples A through I miRNA expressional change is concordant with DNA copy number
status, while box-plot I shows an example (miR-29c) of discordance between expression and copy number (i.e. tumors showing DNA copy number
gain had significantly lower expression).
doi:10.1371/journal.pone.0007850.g005
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to the genomic imbalances, indicating that other factors can
significantly negate the effects of DNA copy number alteration.
For example, miR-29c is expressed at lower levels in MNA tumors
in spite of the fact that it maps to a region on chromosome 1q that
is commonly gained in neuroblastoma. In this instance, and in at
least two additional instances (miR-30a and miR-25), over-
expression of the MYCN oncogene would appear to be the factor
that is over-riding the effect of DNA copy number change.
Many of the miRNAs that are down or up-regulated by either
MYCN or chromosomal imbalances are likely to play key roles in
tumorigenesis. For example, miR-34a mapping to chromosome 1p
is clearly down-regulated by 1p deletion because it targets
important pro-proliferation genes [11,12], while the miR-17-5p
cluster is directly up-regulated by MYCN and targets the p21
tumor suppressor. Wei et al [17] showed that over-expression of
the miR-17-5p-92 cluster host gene, MIRHG1, is correlated with
poor patient survival and that expression of miR17-5p-92 is
positively correlated with host gene expression. Presumably over-
expression of miR-17-5p-92 is also correlated with poor survival,
although this was not directly reported on. Our results indicate a
correlation of over-expression of the miR17-5p-92 cluster
members with poor patient survival (p,0.009), although the p-
value was not significant following a highly conservative correction
for multiple comparisons. In this regard, the lack of a significant p-
value associated with miR-17-5p over-expression and poor
survival is probably a false negative result in our study, particularly
in view of the fact that functional studies of this miRNA in
neuroblastoma have indicated an oncogenic role in neuroblastoma
[13].
Interestingly, miR-29a, which we show to be under-expressed in
MNA tumors, was also recently shown to be down-regulated in
neuroblastoma as it directly targets B7-H3, a cell surface
immunomodulatory glycoprotein which contributes to the process
of immune escape [18]. It is equally important to realize that some
of the dysregulated miRNAs might be passive events and have no
effect on disease pathogenesis. For example, miR-30e was highly
under-expressed in MNA tumors, but we have previously shown
that ectopic over-expression of this miRNA in MNA cell lines has
no detectable impact on cell proliferation [12].
We have also demonstrated that a signature based on the
expression of 37 miRNAs that are differentially expressed in MNA
tumors relative to non-MNA tumors permits the clustering of
patients into two groups that differ significantly in survival.
However, this signature yields P-values that are not as good as the
use of MNA or 11q status by themselves, possibly because some of
the miRNAs in the signature play no role in tumorigenisis (e.g.
miR-30e). The inclusion of these passive miRNAs in the MYCN
miRNA signature could decrease the predicting power of a
miRNA expression signature based on miRNAs identified by their
association with MYCN levels. We therefore developed a miRNA
expression signature by directly identifying the miRNAs that were
most significantly associated with overall survival. Interestingly,
only miR-572 and miR-190 from the set of 15 miRNAs most
closely associated with EFS and OS overlapped the set of 37
miRNAs that were associated with MYCN amplification. This
signature classified patients into groups and subgroups associated
with EFS and OS with p-values that were significantly better than
those obtained with the MYCN associated miRNA signature. This
15 miRNA expression signature requires validation in an
independent tumor set, and represents a method of patient
stratification that is independent of MYCN amplification status.
Under-expression of miRNAs in MNA tumors appears to occur
twice as frequently as over-expression. This observation is
consistent with our studies on a smaller set of miRNAs
(n=150)[14] and with observations on a related family member,
c-MYC [19]. One of the notable miRNAs under-expressed in
MNA tumors was the large polycistronic miRNA 379–656 cluster;
a 44.7 kb polycistron containing 38 miRNAs mapping to
chromosome 14. Four miRNAs from this cluster were expressed
at significantly lower levels in MNA tumors relative to non-MNA
tumors. Gene ontology analysis of predicted gene targets for
miRNAs from this cluster revealed significant over-representation
of biological processes such as neurogenesis, embryonic develop-
ment and transcriptional regulation [20].
Treatment regimens for patients with neuroblastoma catego-
rized as high risk involve intensive, multi-modal chemotherapy.
Despite the severity of treatment, in many cases they have only
short-term effects, emphasizing the fact that accurate identification
of low and high risk is of great importance. The identification of
clinical relevant miRNAs is an initial step towards identifying
miRNAs as significant prognostic markers in neuroblastoma with
potential novel therapeutic applications for this disease.
Materials and Methods
Cell Lines and Reagents
The MYCN-inducible cell line, SHEP-TET21, was obtained
from Dr. Louis Chesler with permission of Prof. Manfred Schwab.
RNA was isolated from this cell line 72 hrs following the addition
of doxycline.
Patient Cohort
Tumor material was obtained from either the Children’s
Oncology Group Tumour Bank (n=108), or the Tumour Bank
at Our Lady’s Children’s Hospital, Dublin (n=37). Patients were
treated under either the U.S. neuroblastoma treatment protocol or
the European treatment protocol between 1998 to 2004. This
work was approved by the Research Ethics Committee of the
Royal College of Surgeons on 16th October 2007 (application
No. REC241) and by the Research Ethics Committee of Our
Lady’s Children’s Hospital on 5th August 2008 (application
number GEN/70/07). The tumour cohort came from patients
with stage 4 (n=74), stage 3 (n=31) and stages 1, 2 and 4s (n=40)
disease (INSS). In total, 36 tumors had MYCN amplification
(MNA) while 42 tumors had loss of 11q without MNA (Table S4).
MYCN amplification and loss of 11q were predictive of both poor
EFS (p,0.0001) and OS (p,0.0001) in this set of 145 tumors
(Figure S2).
miRNA Extraction
Total RNA isolation was preformed using miRNeasy (Qiagen),
as per manufacturers instructions.
qPCR Using Gene Expression Assays
Reverse transcription was carried out with a TaqMan Reverse
Transcription kit using random primers (Applied Biosystems).
PCR amplification reactions contained TaqMan Fast Master Mix,
cDNA and TaqMan probe & primers specific to MYCN and
RPLPO ribosomal protein (Applied Biosystems). Relative quan-
tification of gene expression was determined using the comparative
cycle threshold method (2
2DDCT).
Western Blotting
Denaturing polyacrylamide gel electrophoresis (SDS-PAGE)
followed by immunoblotting for the detection of the antigen
recognised by MYCN antibody (Abcam) were performed by
standard methods.
miRNA and Neuroblastoma
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RNA was reverse transcribed using the miRNA reverse
transcription kit (Applied Biosystems). Cell line RNA was used
in combination with the stem-loop Multiplex primer pools
(Applied Biosystems), allowing reverse transcription of 48 different
miRNA in each of 8 RT pools. The Megaplex primer pool
(Applied Biosystems) was used with RNA from tumor samples,
allowing simultaneous reverse transcription of 430 miRNAs and
36 endogenous controls in one RT pool [21].
Pre-Amplification of cDNA from Clinical Samples
Megaplex RT product (5 ml) was pre-amplified using Applied
Biosystems’ TaqMan PreAmp Master Mix (26) and PreAmp
Primer Mix (56). The PreAmp primer pool contained forward
primers specific for each miRNA, and a universal reverse primer
(Applied Biosystems, early access).
Real-Time qPCR
Cell lines. Each cell line sample was profiled using TaqMan
Low Density Arrays (TLDA) (368TaqMan PCR assays)(Applied
Biosystems).
Tumor samples. For each cDNA sample, 430 miRNAs plus
36 control small RNAs were profiled using individual TaqMan
PCR assays setup in 384-well format. As instrument and liquid
handling variations were shown to be minimal, no PCR replicates
were measured [21].
A Ct value of 35 represents single molecule template detection,
and therefore a Ct value greater than 35 was considered noise. All
miRNAs with Ct values greater than 35 were considered ‘non
amplified’ or ‘not expressed’.
Prior to calculating relative expression values, mean normali-
zation was carried out by subtracting the mean sample Ct from the
individual miRNA Ct values [22]. Normalized relative expression
(NRQ) of miRNA was calculated with reference to the Ct max
(maximum Ct value for an individual miRNA across all tumour
samples) using: NRQ=2
(Ctmax2Ct).
Data Analysis
Micro-RNA profiles for 145 tumors were used in this study. To
investigate which microRNAs varied over the various sample
classes of MNA and non-MNA and Survival and non-Survival we
split these into a training/test set (66%) and a hold-out set (33%). This
latter hold-out data set plays no part in training or testing and is
used to independently validate of findings. The selection was
stratified in that approximately the same rate of deaths occurred in
both the training/test and hold-out sets.
Significance testing. The significance of miRNA differential
expression over tumor sub-types was evaluated by assigning P-
values based on the non-parametric Wilcoxon rank sum test.
Adjustment for multiple comparisons was made using the
Benjamini-Hochberg multiple testing correction. The resultant
set of miRNAs were then examined using hierarchical cluster
analysis and the principal split was found, as expected, to occur
between MNA and non-amplified tumors. A similar investigation
into overall survival (OS) and event free survival (EFS) was also
carried out. In both cases the hold-out set was used to examine the
generalizability of the models.
The Random Forest and feature selection. Random
Forest [23] is an Ensemble Classifier in which the base classifier
is an un-pruned Decision Tree built from a random selection of
feature variables (in this case miRNAs) for a randomly selected
subset of training samples (tumors). The association or importance of
a feature with a particular class may be by garnered by assessing its
impact on classification. This is achieved by randomizing the
feature values over sample classes and re-running the classifier. If
there is a large adverse affect upon the classification the feature
achieves a high importance score. The advantage of an importance
score over simple filtering methods (p-value, information gain etc) is
that multivariate feature interaction effects may be assessed. An
additional advantage of Random Forest is its reduced tendency to
overfit a dataset i.e. when a method models noise within a dataset
and not the phenomenon under investigation. Lastly Random
Forest may be considered a non-parametric method as
information gain is used to build the base decision tree
classifiers. The feature importance score derived from the Random
Forest classifier was used to assess the association of a particular set
of miRNAs with survival. This signature was first developed on the
training/test set of tumors and the hold-out set was used as an
external validation set.
Cluster analysis and visualization. Hierarchical clustering
and heatmap generation was implemented using the hclustp and
heatmap.2 functions of the R statistical computing language v2.8.0.
Statistical analysis of neuroblastoma primary tumors. EFS
time was calculated from the time of enrolment on the front-line or
biologic study until the time of the first occurrence of relapse,
progressive disease, secondary malignancy, or death, or until the time
of last contact if no event occurred. OS time was calculated until the
time of death or until last contact. EFS and OS are presented as the
estimate +/2 the standard error.
Array CGH. Array CGH was carried out as previously
described [24] using a 72,000 feature array (NimbleGen).
Supporting Information
Figure S1 Western blot shows major differences in MYCN
protein levels in: lane 1: a MYCN amplified NBL cell line, Kelly,
lane 2: SHEP-TET21 cells in the absence of doxycycline, lane 3:
SHEP-TET21 cells in the presence of doxycycline.
Found at: doi:10.1371/journal.pone.0007850.s001 (2.88 MB TIF)
Figure S2 Kaplan-Meier plots demonstrating that MNA and
11q loss were both predictive of poor survival in the entire cohort
of 145 tumors.
Found at: doi:10.1371/journal.pone.0007850.s002 (0.16 MB TIF)
Table S1 List of miRNAs expressed in at least 10 tumors
Found at: doi:10.1371/journal.pone.0007850.s003 (0.01 MB
PDF)
Table S2 Differentially expressed miRNAs in SHEP treated (low
MYCN levels) versus SHEP untreated (high MYCN levels)
Found at: doi:10.1371/journal.pone.0007850.s004 (0.01 MB
PDF)
Table S3 MiRNAs With Expression Levels Correlating to
Genomic Imbalances
Found at: doi:10.1371/journal.pone.0007850.s005 (0.05 MB
PDF)
Table S4 Clinical and Genetic Characteristics of Tumor Cohort
Found at: doi:10.1371/journal.pone.0007850.s006 (0.01 MB
PDF)
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